Fosamprenavir Main Page

Medical Advocates
Fosamprenavir (Lexiva/GW433908)

Main Page

New and Noteworthy

Journal Data

Conference Data

FDA Updates
Guidelines

Pediatric Data

Perinatal Data

Protease Inhibitors: General Data

Manufacture's Information
Lexiva December 2007 Revised Label

ARV Drugs Main Page Main New/Newsworthy Home Page

This web page is best viewed by using INTERNET EXPLORER
Last Update: November 25, 2011
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

New and Noteworthy

November 2011

Interactions Between Buprenorphine and the Protease Inhibitors Darunavir-Ritonavir and
Fosamprenavir-Ritonavir
Gruber VA, Rainey PM, Moody DE, et alClin Infect Dis. 2011 Nov 18.

FDA Updates

Cardiovascular Problems with Lexiva (fosamprenavir)

Pediatric Indications

USPHS Pediatric Antiretroviral Drug Information
US Treatment Guidelines

Journal Papers, Abstracts, and Commentaries

Long-Term Efficacy and Safety of Fosamprenavir in Human Immunodeficiency
Virus-Infected Pediatric Patients.
Palladino C, Briz V, Policarpo SN, et al
Pediatr Infect Dis J. 2010 Feb 12
Abstract

Conference Reports, Abstracts and Posters

POSTER
Use and safety of fosamprenavir in HIV-infected children in the European Union: an ongoing
post-marketing surveillance study
A. Judd, L. E, L. Galli, T. Goetghebuer .et al
(6th IAS Conference)
Poster     Abstract

Safety and Antiviral Activity of Fosamprenavir/Ritonavir Once Daily Regimens in HIV-infected
Pediatric Subjects Ages 2 to 18 Years (48-Week Interim Data, Study APV20003)
E Chadwick, W Borkowsky, C Fortuny, et al
(14 CROI)
Abstract

Safety and Antiviral Activity of Fosamprenavir-containing Regimens in HIV-infected 2- to
18-Year-Old Pediatric Subjects (Interim Data, Study APV29005)
C Cunningham, A Freedman, S Read, et al
(14 CROI)
Abstract

Perinatal Data

Guidelines

     United States
          Internet Documents

FULL TEXT PDF DOCUMENT
Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs
in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce
Perinatal HIV Transmission in the United States.
Perinatal HIV Guidelines Working Group.
November 2, 2007
Guidelines

FULL TEXT PDF DOCUMENT
Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy
Perinatal HIV Guidelines Working Group.
November 2, 2007
Guidelines

Conference Reports, Abstracts and Posters

Pharmacokinetics, cord blood concentrations, and tolerability of boosted fosamprenavir (FPV) in pregnancy
M. Cespedes, S. Ford, G. Pakes, et al
(6th IAS Conference)
Abstract

ARV Drugs Main Page Main New/Newsworthy Home Page

Fosamprenavir